EU Bans Illumina's $8B Acquisition Of Grail
IP Law 360
SEPTEMBER 6, 2022
The European Union's antitrust watchdog on Tuesday banned DNA sequencing giant Illumina's $8 billion reacquisition of medical testing company Grail Inc., indicating that it will order the companies to unwind the completed deal to protect competition for new cancer screening tests.
52 
Let's personalize your content